FCA Corp TX lowered its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,655 shares of the medical research company’s stock after selling 835 shares during the quarter. Amgen comprises approximately 1.3% of FCA Corp TX’s portfolio, making the stock its 25th biggest position. FCA Corp TX’s holdings in Amgen were worth $3,416,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in AMGN. Parkside Financial Bank & Trust raised its position in shares of Amgen by 2.6% in the 3rd quarter. Parkside Financial Bank & Trust now owns 1,883 shares of the medical research company’s stock worth $364,000 after purchasing an additional 47 shares during the last quarter. Clear Harbor Asset Management LLC increased its holdings in Amgen by 0.8% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 6,385 shares of the medical research company’s stock worth $1,236,000 after buying an additional 49 shares in the last quarter. Carlton Hofferkamp & Jenks Wealth Management LLC increased its holdings in Amgen by 1.1% in the 3rd quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 4,694 shares of the medical research company’s stock worth $933,000 after buying an additional 50 shares in the last quarter. Concentric Wealth Management LLC increased its holdings in Amgen by 0.4% in the 3rd quarter. Concentric Wealth Management LLC now owns 14,084 shares of the medical research company’s stock worth $2,725,000 after buying an additional 52 shares in the last quarter. Finally, Independence Bank of Kentucky increased its holdings in Amgen by 3.5% in the 3rd quarter. Independence Bank of Kentucky now owns 1,645 shares of the medical research company’s stock worth $318,000 after buying an additional 55 shares in the last quarter. 77.06% of the stock is owned by institutional investors and hedge funds.
Several research firms recently commented on AMGN. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Leerink Swann lifted their price objective on Amgen from $189.00 to $205.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. Cowen set a $231.00 price objective on Amgen and gave the stock a “buy” rating in a report on Sunday, September 29th. Oppenheimer set a $240.00 price objective on Amgen and gave the stock a “buy” rating in a report on Monday, September 9th. Finally, Sanford C. Bernstein began coverage on Amgen in a report on Monday, October 14th. They issued an “outperform” rating for the company. Ten research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $221.47.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, October 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.53 by $0.13. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The business’s quarterly revenue was down 2.8% compared to the same quarter last year. During the same period in the previous year, the company posted $3.69 EPS. Sell-side analysts anticipate that Amgen, Inc. will post 14.44 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 6th. Shareholders of record on Friday, November 15th will be paid a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, November 14th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.64%. Amgen’s dividend payout ratio is currently 40.28%.
In related news, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $215.45, for a total transaction of $91,566.25. Following the completion of the transaction, the director now directly owns 5,413 shares in the company, valued at approximately $1,166,230.85. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $206.70, for a total value of $413,400.00. Following the transaction, the director now owns 16,336 shares of the company’s stock, valued at $3,376,651.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,851 shares of company stock valued at $3,685,674. Corporate insiders own 0.25% of the company’s stock.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: Conference Calls and Individual Investors
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.